Clostridium difficile is an anaerobic, Gram-positive, spore-forming bacillus which is primarily responsible for pseudomembranous colitis (PMC) and antibiotic-associated diarrhoea (AAD). The main virulence factors of C. difficile are the toxins A and B. C. difficile-associated disease (CDAD) ranges from asymptomatic carrier state, diarrhoea, PMC, megacolon to death. [1] The role of asymptomatic colonisation by C. difficile has been assessed in various studies. C. difficile carriage rates in children, adults and healthcare workers were 13.6%, 5.5% and 6.3%, respectively, among healthy individuals in China. [2] The asymptomatic carriage rate was 13% among inpatients in another study. [3] The predisposing factors for C. difficile infection (CDI) are administration of antibiotics, immunosuppressive agents, proton-pump inhibitors, cancer therapeutics and host risk factors such as old age, underlying illnesses and prolonged hospital stay. [4] Although previously recognised as a nosocomial pathogen, now, it is increasingly noticed as a community-acquired one. [5] The laboratory diagnosis of C. difficile is based on the isolation of the organism and the detection of its toxins and toxin-encoding genes. Cell culture cytotoxicity assay, toxigenic culture, enzyme immunoassays (EIAs) for glutamate dehydrogenase (GDH) enzyme and toxins and real-time-polymerase chain reaction (PCR) have been commonly employed in the Purpose: Prevalence of Clostridium difficile, an anaerobic, Gram-positive, spore-forming bacillus, is very much underestimated in India. The present study was intended to assess the burden of toxigenic C. difficile in hospitalised patients with clinically significant diarrhoea and analysis of their clinical picture. Materials and Methods: This cross-sectional study was conducted in a tertiary care teaching hospital, South India, from January 2012 to December 2014. Stool samples were collected consecutively from 563 inpatients from various wards. The prevalence of toxigenic C. difficile was determined by toxigenic culture and a two-step algorithm. The clinical spectrum of these patients was also analysed. Associated pathogens were identified using standard procedures. Statistical analysis was done by frequency, percentage, Chi-square test and z-test. Results: Out of the 563 stool samples analysed, the prevalence of toxigenic C. difficile was 12.79% and that of non-toxigenic C. difficile was 10.83%. The prevalence of toxigenic C. difficile among oncology patients was highly significant (HS). Antibiotic treatment, prolonged hospital stay and underlying diseases/conditions were the risk factors which were HS, and fever was the significant clinical feature among the patients. Escherichia coli was the predominant associated pathogen isolated (18.47%). Conclusion: The presence of toxigenic C. difficile in our locality is a matter of concern. Constant supervision, appropriate treatment and preventive measures are crucial in controlling C. difficile infection.
laboratory diagnosis of C. difficile. [6] A single diagnostic test with high sensitivity, specificity, cost-effectiveness and reliability for the detection of C. difficile is lacking. [7] The present study was intended to assess the burden of C. difficile among patients with clinically significant diarrhoea who were admitted to a tertiary care hospital, South India. Detection of the burden of C. difficile requires the analysis of the prevalence of toxigenic C. difficile (presence of both or either toxin). The criteria employed in our study to detect toxigenic C. difficile were toxigenic culture [6] and a two-step algorithm. [8] Paediatric and oncology patients are regarded as high-risk groups for CDI. Therefore, the prevalence of C. difficile was also noted among these groups in the present study. The study also analyses the significant clinical characteristics of C. difficile-positive patient population.
MaterialS and MethOdS
This cross-sectional study was conducted at a tertiary care teaching hospital of coastal Karnataka, South India. Stool samples were collected consecutively from 563 inpatients with clinically significant diarrhoea who were admitted in various wards such as medicine, paediatrics, surgery, oncology and orthopaedics.
The study was approved by the Institutional Ethics Committee (Ref. No. FMMC/IEC/816/2012). The demographic and clinical details of each patient including age, sex, severity of diarrhoea, usage of antibiotics or other drugs, underlying illnesses and period of hospital stay were extracted from the medical records. Written informed consent was taken from the patients during the study. In case of minors, consent was taken from the guardians of the patients.
The faecal samples were collected in sterile, wide-mouthed containers, and the samples were processed immediately on receipt to the laboratory. The stool specimens were inoculated on cycloserine cefoxitin fructose agar (CCFA) and anaerobically incubated at 37°C for 48 h for the isolation of C. difficile. [9] The colonies on the plate were identified as C. difficile by Gram stain, morphology and characteristic odour and then subjected to latex agglutination (using Oxoid C. difficile Test Kit, DR 1107A, UK) and biochemical reactions [9, 10] for confirmation. Latex agglutination was performed according to the manufacturer's instructions. EIA was done using Premier Toxins A and B (C. difficile) EIA kit M/S (Meridian Bioscience, Cincinnati, OH), according to the manufacturer's instructions, on all the faecal samples for the detection of toxins A and B of C. difficile. The colonies confirmed as C. difficile were then subjected to PCR using Applied Biosystems SimpliAmp Thermal Cycler by thermo fisher scientific (Massachusetts, USA) for the detection of toxin A and toxin B genes. Toxin A gene was detected using two primer pairs: primers NK3 and NK2 and primers NK11 and NK9. [11, 12] Primers NK104 and NK105 were used to detect toxin B gene. [11, 12] C. difficile antigen, GDH, in faecal specimens was also detected by C.DIFF CHEK™-60 test, an EIA by TechLab, Blacksburg, VA, USA according to the manufacturer's instructions.
The criteria employed in the present study to detect toxigenic C. difficile were toxigenic culture [6] and a two-step algorithm. [8] Toxigenic culture is a culture on selective media like CCFA followed by in vitro toxin detection by EIA/cell culture cytotoxicity assay/PCR to analyse the toxigenicity of the isolated strain. [6] The two-step algorithm consists of a combination of a screening test GDH EIA, followed by a more specific test, EIA for toxin A and/or B. [8] Two EIAs were employed because GDH test always has to be followed by a second test as it cannot distinguish the toxigenic and non-toxigenic strains of C. difficile. Thus, the prevalence of toxigenic C. difficile in the present study was obtained by toxigenic culture (culture on CCFA followed by in vitro toxin detection by toxin EIA/PCR) and a two-step algorithm (GDH EIA + toxin EIA).
The patients in the present study were classified into three groups: paediatric patients, oncology patients and other patients (other than oncology and paediatric patients i.e. the patients belonging to the wards of medicine, surgery and orthopaedics) for the investigation of various CDI-associated factors. C. difficile ATCC 43593 was used as the control strain in the study. The significant clinical characteristics of C. difficile-positive patients were also identified by the analysis of medical records.
All the stool samples were subjected to the screening of associated organisms such as aerobic bacteria, fungi and parasites using standard procedures. [13, 14] Rotavirus and adenovirus detection was also performed on paediatric samples. Detection of rotavirus was by a rapid latex agglutination assay using Rotavirus Latex Test Kit from Plasmatec, Dorset, UK according to the manufacturer's instructions. Detection of adenovirus was done by SD Bioline Rota/Adeno Rapid Test kit Standard Diagnostics, Korea, according to the manufacturer's instructions.
Statistical analysis
Data were analysed by frequency, percentage, Chi-square test and z-test.
reSultS
During the study period, 563 stool samples were collected and analysed. A single stool sample was taken from each patient enrolled in the study. The total number of stool samples obtained from each group of patients was as follows: paediatric patients (158), oncology patients (74) and other patients belonging to medicine, surgery and orthopaedic wards were 331. The burden of toxigenic C. difficile was determined by toxigenic culture and a two-step algorithm as shown in Table 1 . The prevalence of toxigenic C. difficile in the present study was 12.79%. Out of 72 patients with toxigenic C. difficile, 18 patients were considered toxigenic by two-step algorithm, as they were culture negative and therefore, PCR could not be conducted on those samples. Among the remaining 54 patients (isolates), 51 (94.44%) had been subjected to PCR, and 50 (98.04%) were positive. Out of these 50 PCR positives, isolates carrying both toxin A and B genes were 6 (12%), isolates with only toxin B gene but not toxin A gene were 40 (80%) and isolates with only toxin A gene but not toxin B gene were 4 (8%), respectively. The prevalence of non-toxigenic C. difficile among 563 patients was 10.83%, as shown in Table 2 .
The analysis of clinical features and risk factors of patients with toxigenic C. difficile was also reviewed and is presented in Table 3 . This was attempted to establish the role of various predisposing factors in causing CDI. Among the 72 patients with toxigenic C. difficile, 32 (44.44%) were male and 40 (55.56%) were female. Fever, antibiotic treatment, prolonged hospital stay and underlying diseases/conditions were the highly significant (HS) factors when statistically compared to other factors among the patients with toxigenic C. difficile. The underlying diseases/conditions were mainly various types of carcinoma (24) , diabetes mellitus (5), hypertension (6), heart diseases (4), kidney diseases (4), pneumonia (2), anaemia (2), bronchial asthma (1), surgery (3), leptospirosis (1), inflammatory bowel disease (1), irritable bowel syndrome (1), ileocolitis (1), sepsis (2), pulmonary kochs (1), antral gastritis (1), fibroid uterus (1), osteoarthritis (1) and viral fever (1) . The comparison of clinical features and risk factors encountered in patients with toxigenic and non-toxigenic C. difficile is summarised in Table 4 . AAD, chemotherapy, prolonged hospital stay and the underlying diseases/conditions were HS among the patients with toxigenic C. difficile, and vomiting and antibiotic treatment were the factors significant among the patients with non-toxigenic C. difficile. Figure 1 depicts the prevalence of toxigenic C. difficile in the three patient categories. Out of the 72 patients with toxigenic C. difficile, 18 (11.39%), 20 (27.03%) and 34 (10.27%) patients belonged to paediatrics, oncology and other wards, respectively. An important finding was that the prevalence of toxigenic C. difficile was statistically significant (χ 2 = 15.22, P = 0.002 < 0.01, HS) in oncology patients compared to the other two groups. Figure 2 depicts the details of antibiotics administered in patients with toxigenic C. difficile. Usage of third-generation cephalosporins, fluoroquinolones and nitroimidazoles was HS (χ 2 = 81.49, P = 0.0001 < 0.01, HS) compared to other antibiotics among the patients with toxigenic C. difficile.
Diarrhoeagenic Escherichia coli was the predominant associated organism isolated from the stool specimens (18.47%).
The other enteric pathogens isolated were Shigella sonnei (0.71%), Shigella flexneri (1.42%) and non-typhoidal Salmonellae (0.89%). Rotavirus was detected in 12 paediatric samples out of 98 (12.24%).
diScuSSiOn
C. difficile, an anaerobic Gram-positive bacillus, is a well-recognised pathogen in the Western countries. There are literature evidences on this pathogen from Asia. [15] The organism is responsible for mere asymptomatic colonisation to even life-threatening complications. [1] The mutant hypervirulent strain, North American pulse-field gel electrophoresis type 1/ restriction endonuclease analysis BI/ribotype 027 (NAP1/ BI/027), which caused outbreaks of CDAD in the USA, Europe, Canada and many parts of the world amplified the [4] and Group **III belongs to two-step algorithm. [6] Thus, the prevalence of toxigenic C. difficile was 12.79%. PCR: Polymerase chain reaction, EIAs: Enzyme immunoassays, GDH: Glutamate dehydrogenase, C. difficile: Clostridium difficile significance of the organism. [1] Many other PCR ribotypes of C. difficile such as 078, 018, 017, 014, 002 and 001 also greatly contributed to CDAD.
Previous literature has revealed that the occurrence of C. difficile varied globally based on various factors. Variation in the results is dependent on factors such as selection of the patient population and inclusion of the type of test for the detection of the pathogen. Different investigators worldwide have reported varied prevalence/incidence rates.
In the present study, the prevalence of toxigenic C. difficile was 12.79%, which is in agreement with a previous study from Jordan which reported a prevalence of 12.65%. [16] Some recent Indian studies have also presented C. difficile prevalence data. A prevalence ranging from 4.32% to 15.7% had been reported from our country. [17] [18] [19] [20] The prevalence of non-toxigenic C. difficile (absence of both toxins) obtained in our study was 10.83%, and these could be regarded only as colonisers. [21] There are many hurdles in the isolation and identification of C. difficile. Anaerobic culture techniques for the isolation of the organism are time consuming. Culture, latex agglutination and GDH EIA cannot differentiate between toxigenic and non-toxigenic C. difficile. The molecular detection of C. difficile though rapid is relatively costly. The techniques used by different laboratories largely depend on the cost and availability of the kits and trained personnel. This large disparity in the techniques for detection of the organism makes interlaboratory results incomparable. We used toxigenic culture [6] and a two-step algorithm [8] to detect toxigenic C. difficile in the present study. The toxigenic culture used in the study was in accordance with the European Society of Clinical Microbiology and Infectious Diseases. The advantage of the culture method is that C. difficile isolates would be available for epidemiological study and antimicrobial Group IV Total number of non-toxigenic C. difficile 61 out of 563 (10.83%) The three Groups (I, II, III) of were found negative for toxins by EIA (for toxins A and/or B) and/or PCR. PCR: Polymerase chain reaction, EIA: Enzyme immunoassay, GDH: Glutamate dehydrogenase, C. difficile: Clostridium difficile susceptibility testing. [22] The two-step algorithm used in our study was in accordance with the Australasian Society for Infectious Diseases guidelines. [8] C. difficile in paediatric patients is a matter of concern which grabbed much attention in the past decade. True infection and colonisation in this group of patients is still unclear. [23] A review of literature has revealed considerable increase in CDI among paediatric population, [24] which is in accordance with the present study. A prevalence of 11.39% was obtained for toxigenic C. difficile among the paediatric patients of this study. Malignancy is a well-recognised predisposing factor for CDI. The prevalence of toxigenic C. difficile in oncology group in the present study was 27.03%, and it was statistically significantly higher compared to other groups (P < 0.01, HS). This was also higher than the rate reported in another study, in which the prevalence of CDI among paediatric oncology patients was 14.4%. [25] The prevalence of toxigenic C. difficile in other patients (other than paediatric population and patients with malignancy) was 10.27% in the present study, which was similar to the isolation rate of Niyogi et al. [26] It is reported that there are diverse established risk factors and clinical features linked with CDI. In the present study, antibiotic treatment, prolonged hospital stay and underlying diseases/conditions were the risk factors which were statistically significant, and the statistically significant clinical feature among the 72 patients with toxigenic C. difficile was found to be fever (χ 2 = 68.91, P = 0.0001 < 0.01, HS). AAD (P = 0.0001 < 0.01, HS), chemotherapy (P = 0.0001 < 0.01, HS), prolonged hospital stay (P = 0.0001 < 0.01, HS) and underlying diseases/ conditions (P = 0.0001 < 0.01, HS) were HS among the patients with toxigenic C. difficile, and vomiting (P = 0.036 < 0.05, significant) and antibiotic treatment (P = 0.002 < 0.01, HS) were the factors significant among the patients with non-toxigenic C. difficile when the risk factors and clinical features were compared among the two groups.
Antibiotic treatment is a well-known predisposing factor for CDI. The finding that prior antibiotic treatment was significant among the CDI patients in the present study was in accordance with the previous literature. [27] Decreasing the length of stay in the health-care setting is important in the reduction of CDI. The present study revealed that prolonged hospital stay was a significant risk factor for CDI patients. Improved hygiene and reduced length of stay in the hospital contributed to reduction in infection rates rather than antimicrobial stewardship and prescription of probiotics. [28] Predisposition of patients with underlying diseases/conditions to CDI has been described by various authors. [29] Furthermore, patients with underlying diseases/conditions showed a greater predilection to CDI in the present study. Fever has been a common clinical symptom observed in CDI patients. In the present study, fever was HS among the patients with toxigenic C. difficile, and this finding has been well supported by literature evidences. [25] The role of different antibiotic classes in CDI was also assessed in the present study, and it was found that usage of third-generation cephalosporins, fluoroquinolones and nitroimidazoles was statistically significant among the patients with toxigenic C. difficile (χ 2 = 81.49, P = 0.0001 < 0.01, HS). In contrast, Leffler and Lamont showed that ampicillin, amoxicillin, cephalosporins, clindamycin and fluoroquinolones had greatest predisposition to CDI. [30] cOncluSiOn To summarise, CDI, which causes severe morbidity and mortality, is underestimated in India due to laborious and costly anaerobic techniques for the isolation and identification of the pathogen. Rapid diagnostic techniques for the detection of C. difficile have not been standardised around the globe. This prospective study employed toxigenic culture for the detection of the organism which has been regarded as gold standard in CDI laboratory diagnosis. Toxigenic C. difficile was also identified in the study using a two-step algorithm based on GDH and toxin detection, which has also been widely recommended by other investigators. The laboratory results need to be correlated with the clinical picture of the patients because asymptomatic colonization is common with C. difficile. In the present study, the clinical picture of the patients was well correlated with the laboratory results.
The presence of toxigenic C. difficile in special populations such as oncology patients must be cautiously dealt with as CDI not only increases the length of hospital stay but also induces a heavy economic burden on the patients. Active surveillance has to be conducted in those populations who are predominantly susceptible to CDI. C. difficile is now an emerging pathogen in India. Various reports from different parts of the country underline the fact that it might set the foothold in our country too in the near future. Constant supervision in the identification of the cases and carriers, appropriate treatment and prevention measures in this regard would yield promising results.
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